NEWS

2024   Technology Networks: The Next Chapter of Science

2024   SebastianStrong Foundation supports Zang Lab research on novel CAR-T therapy treating pediatric rhabdomyosarcoma

2024   The Next Breakthrough Against Cancer?

2024   NextPoint Therapeutics announces first patient dosed in phase 1a/b clinical trial of NPX887, a novel therapeutic targeting HHLA2 to reactivate exhausted T and NK cells in HHLA2+ solid tumors

2024   Endpoints News: Ivan Cheung's post-Eisai life takes hold at NextPoint Therapeutics

2024   Promising new therapy for a hard-to-treat blood cancer

2023   Novel immunotherapy target for breast cancer

2023   Fibroblasts found to promote Glioblastoma tumors

2023   Working with Einstein's OBBD: Know when it's time

2023    A novel immune checkpoint inhibitor TQB2618 from our lab started two new clinical trials:  TQB2618 + anti-PD1 + Anlotinib Hydrochloride Capsules as first-line treatment in 40 patients with advanced hepatocellular carcinoma  and in 75 patients with advanced colorectal cancer.

2023   First Patient for NPX267 Program. NPX267, originally generated in our lab and a first-in-class drug, starts phase I, multicenter, first-in-human clinical trial in six medical centers including Massachusetts General Hospital, MD Anderson Cancer Center, Johns Hopkins University, Montefiore Einstein Cancer Center, Sarah Cannon Research Institute, and NEXT Oncology-San Antonio. The trial includes 131 patients with 12 different types of metastatic solid cancers, including renal cell carcinoma, non-small cell lung cancer, cholangiocarcinoma, colorectal cancer, pancreatic cancer, urothelial carcinoma, gastric gastroesophageal carcinoma, triple negative breast carcinoma, endometrial cancer, cervical cancer, osteosarcoma, and prostate cancer.

2023   Investigational New Drug (IND) application of a first-in-class immune checkpoint inhibitor from our lab received U.S. Food and Drug Administration (FDA) clearance for the first-in-human trial.

2023   How To Turn T Cells Loose. TQB2618, originally generated in our lab, is currently in several phase II and phase I/II clinical trials in 580 patients with 6 different types of advanced solid cancers (nasopharyngeal cancer, non-small cell lung cancer, small cell lung cancer, esophageal cancer, head and neck cancer, melanoma) and 3 different types of recurrent/refractory hematologic cancers (acute myeloid leukemia, myelodysplastic syndromes, lymphoma). 

2023   A novel immune checkpoint inhibitor from our lab started phase 1/2 clinical trial, in combination with anti-PD-1 and chemotherapy, in first-line treatment of 60 patients with relapsed/metastatic head and neck squamous cell carcinoma.

2023   A novel immune checkpoint inhibitor from our lab started phase 1/2 clinical trial, in combination with anti-PD-1 and chemotherapy, in 75 patients with relapsed/metastatic esophageal squamous cell carcinoma.

2023   Endpoints News: Scoop: MPM backs a new checkpoint inhibitor biotech in $80M raise

2023   Developing Novel Checkpoint Inhibitors Against Bladder Cancer

2022   Our new discovery was covered by 68 news articles in 7 languages worldwide

2022   GEN:  First-In-Class Immune Checkpoint Therapy Unlocks NK Cell Attack on Tumors

2022   Les résultats de la recherche pourraient renforcer l’efficacité de la thérapie par points de contrôle immunitaire

2022   Cancro: promettente nuova terapia sviluppata dall’Albert Einstein College of Medicine

2022   Πολλά υποσχόμενη νέα θεραπεία για τον καρκίνο που αναπτύχθηκε από το Κολέγιο Ιατρικής Albert Einstein

2022   El Confidencial:  Las nuevas 'células asesinas' contra el cáncer que pueden cambiarlo todo

2022   Einstein Researchers Develop Promising New Cancer Therapy

2022   A novel immune checkpoint inhibitor from our lab started clinical trial, in combination with anti-PD-L1, to treat 115 patients with non-small cell lung cancer.

2022   A novel immune checkpoint inhibitor from our lab started clinical trial, in combination with anti-PD-L1, to treat 55 patients with small cell lung cancer.

2022   New immune checkpoint inhibitor TQB2618 from our lab started a phase 2 clinical trial to treat 110 patients with recurrent/metastatic nasopharyngeal carcinoma who had failed previous platinum-based chemotherapy and immune checkpoint inhibitors (PD-1/PD-L1, etc.).

2022   A novel immune checkpoint inhibitor from our lab started phase 1/2 clinical trial, in combination with anti-PD-1, to treat 90 patients with relapsed and refractory lymphoma.

2022   A novel immune checkpoint inhibitor from our lab started clinical trial, in combination with demethylation drugs  (Azacitidine, Decitabine), to treat 70 patients with recurrent/refractory acute myeloid leukemia (AML), myelodysplastic syndromes (MDS).

2022   A novel immune checkpoint inhibitor from our lab started clinical trial, in combination with anti-PD-1, to treat 50 patients with advanced melanoma.

2022   Patent [Antagonist Monoclonal Antibodies against Human Immune Checkpoint CEACAM1 (CD66a) and Formulations, Kits, and Methods of Use Thereof] was granted.

2022   Montefiore Einstein Cancer Center Researchers Receive Price Family Foundation Health Equity Research Awards.

2022   Overcoming Resistance to Checkpoint Inhibitor Cancer Therapy.

2022   Checkpoint Protein's Unexpected Role in Fat Metabolism.

2022   Patent was granted.

2021   肿瘤免疫学家臧星星教授: 站在世界药物研发最前列, 展望KIR3DL3-HHLA2新免疫检查点

2021   Promising New Cancer Immunotherapy Drug.

2021   Freeing Immune Cells to Combat Cancer.

2020   A novel immune checkpoint inhibitor derived from our lab started clinical trial to treat  50 cancer patients with advanced solid tumors who had failed standard treatments or lack effective treatments.

2020   Cancer Research Institute CLIP Investigator.

2020   Patent (B7x and Its Derivatives for Treating and Preventing Cardiovascular Disease) was granted.

2019   A new drug company is established based on our research: NextPoint Therapeutics.

2019   MD-PhD student Peter John wins Lasker Essay Contest.

2019   Patent (TMIGD2 and Its Derivatives as Blockers or Binders of Cancer-expressed HHLA2 for Immunotherapies) was granted.

2019   MD/PhD Candidate Makes His Mark on Cancer Research and Bronx Kids' Program.

2018   Patent (HHLA2 as a Novel Inhibitor of Human Immune System and Uses Thereof) was granted.

2018   MD-PhD student Peter John received F30 Individual Predoctoral Fellowship Award from National Institutes of Health.

2017   Zang lab new immunotherapy technologies were licensed to a biotech company in California.

2017   A new pharmaceutical company was established based on our research.

2017   The Zang lab/Einstein and Chia Tai Tianqing Pharmaceutical Group signed an agreement to develop new immunotherapy drugs.

2016   Patent (Antibodies to Human B7x for Treatment of Cancer. Inventors: XingxingZang, James P. Allison) was granted.

2016   MD-PhD student Jordan Chinai received the first Barry R. Bloom Speaker Award.

2016   The Zang lab/Einstein and Jiangsu Hengrui Medicine Co signed an agreement to develop novel immunotherapy for human diseases.

2015   Xingxing Zang received Lustgarten-eBioscience Memorial Award, American Association of Immunologists.

2015   The Zang lab and Pfizer to jointly develop novel drugs for treating human cancers.

2015   Congressionally Directed Medical Research Programs.

2014   Pinpointing Role of B7 

2014   MD-PhD student Kim Ohaegbulam received NRSA F31 Individual Predoctoral Fellowship Award from National Institutes of Health.

2014   Hitting Them with Her Best Shot: An Einstein Alum Talks to Kids about Vaccines.

2013   Our new cancer immunotherapy technology was licensed to a pharmaceutical company.

2013   MD-PhD student Kim Ohaegbulam was invited as a Keynote Speaker for the Annual Moffitt Student Research Day at the Moffitt Cancer Center, Florida.

2013   Regulating Human Immune Response

2008   Xingxing Zang received NIH Director’s New Innovator Award (NIH Type 1 Diabetes Pathfinder Award).

2006   New Scientist magazine.